Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors.

about

Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors.

Item

http://www.wikidata.org/entity/Q39817335

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@en

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@nl

type

Item

label

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@en

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@nl

prefLabel

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@en

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@nl

P1476

Helper and cytotoxic T-cell su ...... lignant salivary gland tumors.

@en

P2093

B Khademi

http://www.w3.org/2001/XMLSchema#string

P2860

Lymphocytes in cancer development: polarization towards pro-tumor immunity

Management and outcome of patients with malignant salivary gland tumors.

IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.

Heterogeneity in the differentiation and function of CD8⁺ T cells.

The 3 major types of innate and adaptive cell-mediated effector immunity.

Targeting of IL-4 and IL-13 receptors for cancer therapy.

Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin.

Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.

Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.

P304

566-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ODI.12496

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27120402

http://www.w3.org/2001/XMLSchema#string